Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium‐glucose co‐transporter‐2 inhibitor: The Impact GLP‐1 CKD study
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15834 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Lisa Chu und 3 weiteren Autor:innen. Beteiligte Einrichtung: LMC Diabetes & Endocrinology, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Hypoglycemic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To compare the effectiveness of adding a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) with adding basal insulin among adults with type 2 diabetes (T2D) and chronic kidney disease (CKD) already treated with a sodium‐glucose co‐transporter‐2 inhibitor (SGLT2i) and not reaching their glycaemic control targets.
Methods
A retrospective analysis of the Canadian LMC Diabetes Registry was conducted. Adults who initiated a GLP‐1 RA were matched 1:1 to adults who initiated basal insulin in a T2D and CKD population. Changes in metabolic outcomes were evaluated at 26‐52 weeks following the therapy start date.
Results
Propensity score matching was used to match participants who initiated a GLP‐1 RA to participants who initiated basal insulin ( n = 153/cohort). A significantly greater reduction in HbA1c at 26‐52 weeks of follow‐up was observed in the GLP‐1 RA cohort compared with the basal insulin cohort (−1.3% ± 1.4% vs. −1.1% ± 1.4%, P = .03). Weight was significantly reduced (−3.4 ± 3.7 vs. 2.6 ± 4.5 kg, P < .001), and the estimated glomerular filtration rate decline slowed significantly (−0.3 ± 8.2 vs. −2.4 ± 10.4 mL/min/1.73m 2 , P = .02), but the change in albuminuria was not significantly different (−5.7 ± 38.1 vs. −0.5 ± 38.3 mg/mmol, P = .47) at follow‐up in the GLP‐1 RA group compared with the basal insulin group. No differences in self‐reported hypoglycaemic events per week and therapy discontinuations were reported between the cohorts.
Conclusions
The study shows the real‐world effectiveness of GLP‐1 RA therapy for T2D and CKD. GLP‐1 RAs provided superior reductions in HbA1c and weight, and greater kidney protection, compared with basal insulin among adults with T2D and CKD already treated with an SGLT2i.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LMC Diabetes & Endocrinology, Toronto, Ontario, Canada.
- Novo Nordisk Canada Inc, Mississauga, Ontario, Canada.
ORCID-Profile: Alexander Abitbol
Zitieren
APA
Chu, L., Bradley, R. M., Auerbach, P., & Abitbol, A. (2024). Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium‐glucose co‐transporter‐2 inhibitor: The Impact GLP‐1 CKD study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15834
Vancouver
Chu L, Bradley RM, Auerbach P, Abitbol A. Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium‐glucose co‐transporter‐2 inhibitor: The Impact GLP‐1 CKD study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15834
BibTeX
@article{Chu2024,
author = {Chu, Lisa and Bradley, Ryan M and Auerbach, Pernille and Abitbol, Alexander},
title = {Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium‐glucose co‐transporter‐2 inhibitor: The Impact GLP‐1 CKD study},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15834}
}
EUVIMED